longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AstraZeneca

AZN

162.9700.69% ( +1.120 )
Trading: Sep 16, 14:11:19 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI

Current ValuationThe current P/E ratio is 24.03, below the reasonable range, cheaper than 88.64% of the time in the past 5 years, and the industry ranks 42/257, the industry Median -1.31.

24.03xP/E
$161.85Stock price
$6.74Earnings per share
24.03xP/E
Stock price$161.85Earnings per share$6.74

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
33.65x
Typical range
27.96x–49.94x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
RHHVFUSROCHE HOLDINGS AG
24.82x--$383.69B
RHHBYUSRoche
22.65x--$350.23B
NVSUSNOVARTIS AG
20.65x1.82%$263.48B
AZNUSAstraZeneca
24.03x--$251.02B
SNYNFUSSanofi
22.64x--$104.04B
SNYUSSanofi
22.11x20.80%$101.60B
CHGCYUSChugai Pharmaceutical
22.71x--$68.38B
MKKGYUSMerck
23.83x--$65.55B
RDYUSDr Reddys Laboratories
26.70x11.22%$9.62B
LGNDUSLigand Pharmac-B
28.00x14.55%$5.52B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.